EP1633713A1 - Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3 - Google Patents

Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3

Info

Publication number
EP1633713A1
EP1633713A1 EP04739742A EP04739742A EP1633713A1 EP 1633713 A1 EP1633713 A1 EP 1633713A1 EP 04739742 A EP04739742 A EP 04739742A EP 04739742 A EP04739742 A EP 04739742A EP 1633713 A1 EP1633713 A1 EP 1633713A1
Authority
EP
European Patent Office
Prior art keywords
malignant
compounds
neopropathy
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04739742A
Other languages
German (de)
English (en)
Inventor
Andreas Huth
Martin Krueger
Ludwig Zorn
Stuart Ince
Rolf Bohlmann
Karl-Heinz Thierauch
Andreas Menrad
Martin Haberey
Holger Hess-Stumpp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP1633713A1 publication Critical patent/EP1633713A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to new VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridones and their use as medicaments for the treatment of diseases which are triggered by persistent angiogenesis.
  • Persistent angiogenesis can be the cause or prerequisite for various diseases such as tumor or metastasis growth, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic malignant nephropathy, nephropathic nephropathy Syndromes, transplant rejections and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases and arteriosclerosis or lead to an exacerbation of these diseases.
  • diseases such as tumor or metastasis growth, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma
  • eye diseases such as diabetic retinopathy, neovascular glaucoma
  • kidney diseases such as
  • Persistent angiogenesis is induced by the factor VEGF via its receptor.
  • VEGF binds to the receptor and tyrosine phosphorylation is caused.
  • VEGF vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • anthranylamidopyridonamides are known which are used as medicaments for the treatment of psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopatic syndromes, transplant rejection and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, Injuries to nerve tissue and to inhibit the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after the insertion of mechanical devices to keep vessels open, such as. B. stents are used.
  • the compounds known from WO 00/27820 are given in the
  • WO 03/040102 discloses anthranyl amides, which are effective, but also show good inhibition of the cytochrome P 450 isoenzyme 3A4.
  • the cytochrome P 450 isoenzyme 3A4 is one of the essential metabolic enzymes through which drugs are broken down. Inhibition of this isoenzyme leads to undesirable drug interactions, especially in multimorbid (multiple disease) patients. There is also the problem that a combination therapy with other drugs leads to increased toxicity, which results from the inhibition of the breakdown of the compounds and the associated excessive serum levels.
  • (I) in the A represents an aryl or heteroaryl
  • X represents hydrogen or fluorine
  • R 1 and R 2 independently of one another for hydrogen, halogen, Ci-C- ⁇ 2 alkyl,
  • Y stands for a bond or for oxygen or for the group -S-, -S (O) - or -SO 2 -, and their isomers, enantiomers,
  • Alkyl is in each case a straight-chain or branched alkyl radical, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. To understand butyl, pentyl, isopentyl or hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl.
  • Alkoxy is in each case a straight-chain or branched alkoxy radical, such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec.
  • alkoxy radical such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec.
  • alkoxy such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec.
  • alkoxy such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec.
  • pentyloxy isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyl
  • Cycloalkyl is to be understood as meaning monocyclic alkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, but also bicyclic rings or tricyclic rings such as, for example, adamantanyl.
  • the cycloalkyl radicals can contain one or more heteroatoms, such as oxygen, sulfur and / or nitrogen, instead of the carbon atoms.
  • heterocycloalkyls having 3 to 8 ring atoms are preferred.
  • Halogen is to be understood as fluorine, chlorine, bromine or iodine.
  • Haloalkyl is understood to mean an alkyl radical which can be substituted one or more times by halogen.
  • the aryl radical contains 3 to 12 carbon atoms and can be benzo-fused.
  • Examples include: cyclopropenyl, cyclopentadienyl, phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, azulenyl, biphenyl, fluorenyl, anthracenyl etc.
  • the heteroaryl radical each comprises 3-16 ring atoms and can contain one or more identical or different heteroatoms, such as oxygen, nitrogen or sulfur in the ring, instead of carbon, and can be mono-, bi- or tricyclic, and can additionally be benzo-fused in each case ,
  • Examples include:
  • the physiologically compatible salts of organic and inorganic bases are suitable as salts, such as the readily soluble alkali and alkaline earth metal salts and N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1, 6-hexadiamine, ethanolamine, Glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, sovak base, 1-amino-2,3,4-butanetriol.
  • physiologically compatible salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, fumaric acid and others.
  • X represents hydrogen or fluorine
  • R 1 and R 2 independently of one another are hydrogen, halogen, C 1 -C 12 -alkyl,
  • Ci-Ci 2 -AIkOXy - d-Cio-alkylene HaIo- C 1 -C 10 -AlKyI, C 3 -C 10 -cycloalkyl or halo-C 3 -C 10 -cycloalkyl and
  • Y stands for a bond or for oxygen or for the group -S-, -S (O) - or -SO 2 -, and their isomers, enantiomers, diastereomers and salts.
  • X represents hydrogen or fluorine
  • R 1 and R 2 independently of one another are hydrogen, halogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkoxy, C r C 10 -alkylene, halo-Crdo-alkyl, C 3 -C 10 -cycloalkyl or halo- C 3 -C 10 cycloalkyl and
  • Y stands for a bond or for oxygen or for the group -S-, -S (O) - or -SO 2 -, and their isomers, enantiomers, diastereomers and salts.
  • Preferred compounds of the general formula I are those in which A represents a phenyl
  • R 1 and R 2 independently of one another are hydrogen, halogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkoxy-dC ⁇ -alkylene, HaIo-C r C 10 -alkyl, C 3 -C 10 -cycloalkyl or HaIo -C 3 -C 1 o-cycloalkyl and
  • Y stands for a bond or for oxygen or for the group -S-, -S (O) - or -SO 2 -, and their isomers, enantiomers, diastereomers and salts.
  • the compounds of general formula I according to the invention also include the possible tautomeric forms and include the E or Z isomers or, if a chiral center is present, also the racemates and enantiomers.
  • the compounds of the formula I and their physiologically tolerable salts can be used as medicaments on account of their inhibitory activity with regard to phosphorylation of the VEGF receptor. On the basis of their activity profile, the compounds according to the invention are suitable for the treatment of diseases which are caused or promoted by persistent angiogenesis.
  • the compounds of the formula I are identified as inhibitors of the tyrosine kinases KDR, FLT-1 and FLT-4, they are particularly suitable for the treatment of diseases which are caused by persistent angiogenesis triggered by the VEGF receptor or an increase in vascular permeability or be promoted.
  • the present invention also relates to the use of the compounds according to the invention as inhibitors of the tyrosine kinases KDR, FLT-1 and FLT-4.
  • the present invention thus also relates to medicaments for the treatment of tumors and their use.
  • the compounds of the invention can be used either alone or in formulation as a medicament for the treatment of tumor or metastatic growth, psoriasis, Kaposis sarcoma, restenosis, such as. B. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkins disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma,
  • Eye diseases such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopatic syndromes, transplant rejection and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferation
  • VEGF-related edema can also be suppressed.
  • Lymphangiogenesis plays an important role in lymphogenic metastasis (Karpanen, T. et al., Cancere Res. 2001 Mar 1, 61 (5): 1786-90, Veikkola T. et al., EMBO J. 2001, Mar 15; 20 (6): 1223-31).
  • the compounds according to the invention now also show excellent activity as VEGFR kinase 3 inhibitors and are therefore also suitable as effective inhibitors of lymphangiogenesis.
  • Treatment with the compounds according to the invention not only reduces the size of metastases, but also reduces the number of metastases.
  • Such drugs, their formulations and uses are also the subject of the present invention.
  • the invention thus further relates to the use of the compounds of general formula I for the manufacture of a medicament for use as or for the treatment of psoriasis, Kaposis sarcoma, restenosis, such as. B. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkins disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic malignant nephropathy, nephropathy .
  • Transplant rejection and glomerulopathy fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to the nerve tissue and to inhibit the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after the insertion of mechanical devices for keeping vessels open, such as, for. B. stents, as immunosuppressants, as support for scar-free wound healing, age spots and contact dermatitis.
  • VEGF-related edema can also be suppressed.
  • a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, milk sugar , Starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic, milk sugar , Starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions.
  • auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surfactant auxiliaries such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
  • Tablets, coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as lactose, are particularly suitable for oral use.
  • Corn or potato starch suitable. It can also be used in liquid form, for example as a juice, to which a sweetener or, if necessary, one or more flavorings is added.
  • the dosage of the active ingredients can vary depending on the route of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors.
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, whereby the dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
  • R x preferably for d-C ⁇ -alky! stands. If R x is C 1 -C 6 alkyl, it may also be optionally saponified first and then converted into the corresponding amide.
  • the reductive amination is carried out using aldehydes or ketones, the reaction being carried out in the presence of a reducing agent such as sodium cyanoborohydride in a suitable inert solvent such as ethanol at temperatures from 0 ° C. to the boiling point of the solvent.
  • a reducing agent such as sodium cyanoborohydride
  • a suitable inert solvent such as ethanol
  • acids such as glacial acetic acid can prove to be advantageous.
  • This reaction sequence can be carried out as a one-pot reaction. It can prove to be advantageous to isolate the amine initially formed and then to reduce it in a separate step, for example with sodium borohydride in solvents such as acetonitrile.
  • the amide formation takes place according to methods known from the literature.
  • An appropriate ester can be used to form the amide.
  • the ester is reacted with aluminum trimethyl and the corresponding amine in solvents such as toluene at temperatures from 0 ° C. to the boiling point of the solvent. If the molecule contains two ester groups, both are converted into the same amide.
  • solvents such as toluene at temperatures from 0 ° C. to the boiling point of the solvent.
  • the molecule contains two ester groups, both are converted into the same amide.
  • aluminum trimethyl sodium hexamethyl disilazide can also be used.
  • all methods known from peptide chemistry are also available for amide formation.
  • aprotic polar solvents such as dimethylformamide
  • an activated acid derivative for example obtainable with hydroxybenzotriazole and a carbodiimide such as diisopropylcarbodiimide, at temperatures between 0 ° C. and the
  • Boiling point of the solvent preferably reacted at 8O 0 C with the amine.
  • the reaction between carboxylic acid and amine can also be carried out by activating reagents such as HATU (N-dimethylamino-1 H-1, 2,3-triazolo- [4,5-b] pyridine-1-ylmethylene] -N-methylmethanaminium hexafluorophosphate-N -oxide), polar aprotic solvents such as
  • Dimethylformamide are suitable for the reaction.
  • a base such as N-methylmorpholine is necessary.
  • the reaction takes place at temperatures of 0-100 0 C, preferably carried out at room temperature.
  • the process via the acid halide, the mixed acid anhydride, imidazolide or azide can also be used for the amide formation.
  • Prior protection of an additional amino group, for example as an amide, is not necessary in all cases, but can have a favorable effect on the reaction.
  • the sulfur is oxidized using methods known from the literature. So you can implement the sulfur compound with oxidizing agents such as m-chloroperbenzoic acid in solvents such as dichloromethane, whereby a mixture of sulfoxide and sulfone can be obtained. Hydrogen peroxide can also be used as an oxidizing agent in solvents such as glacial acetic acid. Oxidation with sodium periodate in the presence of ruthenium trichloride in solvents such as acetonitrile with carbon tetrachloride or sodium periodate in methanol with water is also possible, the sulfone predominantly being formed in the former method, the sulfoxide being formed in the latter. Preparation of the compounds according to the invention
  • Stock solutions Stock solution A: 3mM ATP in water pH 7.0 (-70 0 C)
  • Substrate solvent 1OmM DTT, 10 mM manganese chloride, 100 mM magnesium chloride
  • Enzyme solution 120 mM Tris / HCl, pH 7.5, 10 ⁇ M sodium vanadium oxide
  • 10 ⁇ l substrate mix (10 ⁇ l VoI ATP stock solution A + 25 ⁇ Ci g-33P-ATP (approx. 2.5 ⁇ l of stock solution B) + 30 ⁇ l poly- (Glu4Tyr) stock solution C + 1, 21ml Substrate solvent), 10 ⁇ l inhibitor solution (substances corresponding to the dilutions, as a control 3% DMSO in substrate solvent) and 10 ⁇ l enzyme solution (11, 25 ⁇ g
  • Enzyme stock solution (KDR, FLT-1 or FLT-4 kinase) are diluted in 1, 25ml enzyme solution at 4 ° C). It is mixed thoroughly and incubated at room temperature for 10 minutes. Then add 10 ⁇ l stop solution (25OmM EDTA, pH 7.0), mix and transfer 10 ⁇ l of the solution to a P 81 phosphocellulose filter. It is then washed several times in 0.1 M phosphoric acid. The filter paper is dried, coated with Meltilex and measured in the micro beta counter.
  • the IC50 values are determined from the inhibitor concentration which is necessary to inhibit phosphate incorporation to 50% of the uninhibited incorporation after deduction of the blank value (EDTA stopped reaction).
  • cytochrome P450 inhibition was according to the publication by Crespi et al. (Anal. Biochem., 248, 188-190 (1997)) using baculovirus / insect cell-expressed and human cytochrome P 450 isoenzyme (3A4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention se rapporte à des anthranylamide pyridones sélectionnées qui inhibent VEGFR-2 et VEGFR-3, ainsi qu'à leur utilisation en tant que médicaments pour traiter des maladies déclenchées par une angiogenèse persistante.
EP04739742A 2003-06-13 2004-06-09 Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3 Withdrawn EP1633713A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10327719A DE10327719A1 (de) 2003-06-13 2003-06-13 VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
PCT/EP2004/006236 WO2004111005A1 (fr) 2003-06-13 2004-06-09 Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3

Publications (1)

Publication Number Publication Date
EP1633713A1 true EP1633713A1 (fr) 2006-03-15

Family

ID=33520741

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04739742A Withdrawn EP1633713A1 (fr) 2003-06-13 2004-06-09 Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3

Country Status (18)

Country Link
EP (1) EP1633713A1 (fr)
JP (1) JP2006527228A (fr)
KR (1) KR20060021887A (fr)
CN (1) CN1805936A (fr)
AU (1) AU2004247377A1 (fr)
BR (1) BRPI0411360A (fr)
CA (1) CA2526041A1 (fr)
CR (1) CR8127A (fr)
DE (1) DE10327719A1 (fr)
EA (1) EA200501885A1 (fr)
EC (1) ECSP066280A (fr)
IL (1) IL171898A0 (fr)
MX (1) MXPA05013586A (fr)
NO (1) NO20060196L (fr)
RS (1) RS20050831A (fr)
UA (1) UA81323C2 (fr)
WO (1) WO2004111005A1 (fr)
ZA (1) ZA200600291B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060071812A (ko) * 2004-12-22 2006-06-27 주식회사 엘지생명과학 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체
US9376393B2 (en) * 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CN106496107A (zh) * 2016-08-31 2017-03-15 浙江永宁药业股份有限公司 Vegfr‑2抑制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
WO2002090352A2 (fr) * 2001-05-08 2002-11-14 Schering Aktiengesellschaft Anthranylamides pyridine amides selectives en tant qu'inhibateurs vegfr-2 et vegfr-3
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
DE10228090A1 (de) * 2002-06-19 2004-01-15 Schering Ag Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004111005A1 *

Also Published As

Publication number Publication date
CA2526041A1 (fr) 2004-12-23
DE10327719A1 (de) 2005-01-20
AU2004247377A1 (en) 2004-12-23
EA200501885A1 (ru) 2006-06-30
MXPA05013586A (es) 2006-03-09
RS20050831A (sr) 2008-04-04
WO2004111005A1 (fr) 2004-12-23
KR20060021887A (ko) 2006-03-08
JP2006527228A (ja) 2006-11-30
CR8127A (es) 2006-05-29
ZA200600291B (en) 2007-03-28
IL171898A0 (en) 2006-04-10
NO20060196L (no) 2006-01-12
BRPI0411360A (pt) 2006-07-25
UA81323C2 (en) 2007-12-25
ECSP066280A (es) 2006-07-28
CN1805936A (zh) 2006-07-19

Similar Documents

Publication Publication Date Title
EP1392680B1 (fr) Anthranylamides pyridine amides selectives en tant qu'inhibateurs vegfr-2 et vegfr-3
DE60315516T2 (de) Pyridazinon-derivate als cdk2-hemmer
DE69418461T2 (de) Neue 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazol-derivate
DE10023486C1 (de) Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
WO2001085715A2 (fr) Aza- et polyazanthranylamides et leur utilisation comme medicaments
EP1594841A1 (fr) Anthranylamidopyrimidines inhibant vegfr-2 et vegfr-3
RU2415850C2 (ru) Новые антраниламидопиридинмочевины в качестве ингибиторов киназы рецептора vegf
EP1387838B1 (fr) Derives de cyanoanthranylamide et leur utilisation comme medicament
DE10021246A1 (de) Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
EP1389201A1 (fr) Derives de n-oxyde anthranylamide et leur utilisation en tant que produits pharmaceutiques
DE10023485A1 (de) Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE102004050196A1 (de) Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE3855549T2 (de) Benzimidazol-Derivate und therapeutische, diese enthaltende Mittel gegen Ulcer
US20070135489A1 (en) Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridones
EP1633713A1 (fr) Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3
DE10228090A1 (de) Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel
DE3310796A1 (de) Substituierte ethenylderivate von 1h-pyrazolo-(1,5-a)-pyrimidin, verfahren zur herstellung derselben, sowie diese enthaltende pharmazeutische praeparate
DE10123574A1 (de) Selektive Anthranylamid-Derivate als VEGFR II Inhibitoren
DE10123573B4 (de) N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
RU2299208C2 (ru) Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
DE10125294A1 (de) Selektive Anthranylamid-Derivate als VEGFR-2 und VEGFR-3 Inhibitoren
DE10164590A1 (de) Anthranylamidpyridinamide als VEGFR-2 und VEGFR-3 Inhibitoren
DE10123587B4 (de) Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE10125293A1 (de) N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel (II)
DE10328036A1 (de) VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20090812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091223